The multiparametric scanning system for evaluation of minimal residual disease in hematological malignancies

Acta Haematologica

Volumn 112, Issue 1-2, 2004, Pages 24-29

  Trakhtenbrot, Luba ^a   Rechavi, Gideon ^b   Amariglio, Ninette ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Combined analyses; Fluorescence in situ hybridization; Minimal residual disease

Indexed keywords

BLAST CELL; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER DIAGNOSIS; CELL LINEAGE; CHIMERA; CHROMOSOME ANALYSIS; CONFOCAL LASER MICROSCOPY; CORRELATION ANALYSIS; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION;

CELL SIZE; CYTODIAGNOSIS; HEMATOLOGIC NEOPLASMS; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM, RESIDUAL;

EID: 2642516944     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077556     Document Type: Review

References (28)

1. Campana D, Pui CH: Detection of minimal residual disease in acute lymphoblastic leukemia: Methodological advances and clinical significance. Blood 1995;85:1416-1434.
2. Faderl S, Kurzrock R, Estron Z: Minimal residual disease in hematological disorders. Arch Pathol Lab Med 1999;123:1030-1034.
3. Cohen N, Novikov I, Hardan I, Esa A, Brok-Simoni F, Amariglio N, Rechavi G, Ben-Bassat I, Trakhtenbrot L: Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of CML patients by FISH technique. Cancer Genet Cytogenet 2000;123:102-108.
4. Engel HH, Goddacre A, Keyhani H, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M: Detection of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in clinical remission by molecular cytogenetics. Blood 1995;86(suppl 1):1059.
5. Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M: Minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes: A follow-up of patients in clinical remission. Br J Haematol 1997;99:64-75.
6. Bernell P, Arvidson I, Jacobsson B, Hast R: Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukemia. Br J Haematol 1996;95:666-672.
7. Van Lom K, Houstmuller AB, van Putten WL, Slater RM, Lowenberg B: Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy. Genes Chromosomes Cancer 1999;25:332-338.
8. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF, Roberts WM: Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997;336:317-323.
9. Kusec R, Laczika K, Knobl P, Fiedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B: AML1-ETO fusion mRNA can be detected in remission blood samples of all patients with t(8:21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:735-739.
10. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-3367.
11. Trakhtenbrot L, Reichart M, Shimoni A: Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (Duet™) combined morphological and cytological analysis. Leukemia 2002;16:1419-1422.
12. Bielorai B, Golan H, Trakhtenbrot L, Reichart M, Toren A, Daniely M, Zilberstein Y, Amariglio N, Rechavi G, Kaplinsky C: Combined analysis of morphology and FISH in follow-up of minimal residual disease (MRD) in a child with Ph+ acute lymphoblastic leukemia (ALL). Cancer Genet Cytogenet 2002;138:64-68.
13. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006.
14. Kaplinsky C, Hardan I, Toren A, Reichart M, Daniely M, Zilberstein Y, Bielorai B, Shimoni A, Avigdor A, Nagler A, Rechavi G, Amariglio N, Trakhtenbrot L: Minimal residual disease and chimerism detection after bone-marrow transplantation using an automatic cell scanning system. 43rd ASH Annual Meeting (abstract 5159). Blood 2001;98/2:348b.
15. Kaplinsky C, Hardan I, Toren A, Reichart A, Daniely M, Zilberstein Y, Shimoni A, Avigdor A, Brok-Simoni F, Rechavi G, Amariglio N, Trakhtenbrot L: Combined analysis of morphology and FISH using an automatic cell scanning system, increases the accuracy of leukemia diagnosis. 43rd ASH Annual Meeting (abstract 4451). Blood 2001;98/2:189b.
16. Shimoni A, Trakhtenbrot L, Reichart M, Daniely M, Zilberstein Y, Brok-Simoni F, Rechavi G, Amariglio N, Kaplinsky C: Chimerism testing and detection of minimal residual disease in a patient with Ph+ acute lymphoblastic leukemia after bone marrow transplantation using multiparametric cell scanning system (BioView Ltd. Israel) (abstract 5176). 43rd ASH Annual Meeting. Blood 2001;98/2:352b.
17. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshurun M, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L: Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using BioView (Duet™) combined morphological and cytogenetical analysis. Leukemia 2002;16:1413-1418.
18. Shimoni A, Nagler A, Bielorai B, Reichart M, Rothman R, Toren A, Rechavi G, Amariglio N, Trakhtenbrot L: Detection of host blasts but not mature hematopoietic cells among minute host populations remaining after allogenetic transplantation, using combined morphology and cytogenetic analysis, predicts imminent relapse. 44th ASH Annual Meeting (abstract 2485). Blood 2002;100/1:631a.
19. Shimoni A, Trakhtenbrot L, Bielorai B, Reichart M, Rothman R, Toren A, Rechavi G, Nagler A: Application of immune-therapeutic interventions after allogeneic transplantation based on MRD detection with combined morphological and cytogenetic analysis. Biol Bone Marrow Transplant 2003;9:68.
20. Hardan I, Nagler A, Reichart M, Shimoni A, Rothman R, Daniely M, Kaplan T, Brok-Simoni F, Rechavi G, Amariglio N, Trakhtenbrot L: Detection of 13q deletion in the bone marrow cells of patients with multiple myeloma using combined morphology and FISH analysis. 44th ASH Annual Meeting (abstract 1522). Blood 2002;100/1:392a.
21. Hardan I, Trakhtenbrot L, Rothman R, Reichart M, Shimoni A, Brok-Simoni F, Rechavi G, Amariglio N, Nagler A: Monitoring of minimal residual disease in the bone marrow of patients with multiple myeloma after allogeneic stem cell transplantation by combined morphological and cytogenetic analysis. 9th International Workshop of Multiple Myeloma (abstract 210). Hematol J 2003;4:S76.
22. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J: Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2002;95:1925-1930.
23. Fonseca R, Harrington D, Oken M, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay N, Van Ness B, Greipp PR: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 2002;62:715-720.
24. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY: Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-1571.
25. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R: Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-2191.
26. Nickenig C, Lang NK, Schoch C, Hiddemann W, Haferlach T: New insights into the biology of multiple myeloma using a combination of May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Ann Hematol 2001;80:662-668.
27. Ng MH, Kan A, Chung YF, Wong IH, Lo KW, Wickham NW, Lei KI, Lee JC: Combined morphological and interphase fluorescence in situ hybridization study in multiple myeloma of Chinese patients. Am J Pathol 1999;154:15-22.
28. Harrison CJ, Mazzullo H, Cheung KL, Gerrard G, Jalali GR, Mehta A, Osier DG, Orchard KH: Cytogenetics of multiple myeloma: Interpretation of fluorescence in situ hybridization results. Br J Haematol 2003;120:944-952.